BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30002810)

  • 1. Mutant huntingtin induces iron overload via up-regulating IRP1 in Huntington's disease.
    Niu L; Ye C; Sun Y; Peng T; Yang S; Wang W; Li H
    Cell Biosci; 2018; 8():41. PubMed ID: 30002810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear translocation of STAT5 initiates iron overload in huntington's disease by up-regulating IRP1 expression.
    Niu L; Zhou Y; Wang J; Zeng W
    Metab Brain Dis; 2024 Apr; 39(4):559-567. PubMed ID: 38261161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adeno-Associated Viral Vector Serotype DJ-Mediated Overexpression of N171-82Q-Mutant Huntingtin in the Striatum of Juvenile Mice Is a New Model for Huntington's Disease.
    Jang M; Lee SE; Cho IH
    Front Cell Neurosci; 2018; 12():157. PubMed ID: 29946240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
    Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
    Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of interleukin-1 type 1 receptor enhances the accumulation of mutant huntingtin in the striatum and exacerbates the neurological phenotypes of Huntington's disease mice.
    Wang CE; Li S; Li XJ
    Mol Brain; 2010 Nov; 3():33. PubMed ID: 21044321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
    Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
    Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron activates microglia and directly stimulates indoleamine-2,3-dioxygenase activity in the N171-82Q mouse model of Huntington's disease.
    Donley DW; Realing M; Gigley JP; Fox JH
    PLoS One; 2021; 16(5):e0250606. PubMed ID: 33989290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral vector mediated expression of mutant huntingtin in the dorsal raphe produces disease-related neuropathology but not depressive-like behaviors in wildtype mice.
    Pitzer M; Lueras J; Warden A; Weber S; McBride J
    Brain Res; 2015 May; 1608():177-90. PubMed ID: 25732261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
    Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
    J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of zinc transporter ZnT3 transcriptional activity and synaptic vesicular zinc in the brain of Huntington's disease transgenic mouse.
    Niu L; Li L; Yang S; Wang W; Ye C; Li H
    Cell Biosci; 2020; 10():106. PubMed ID: 32944220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear-targeting of mutant huntingtin fragments produces Huntington's disease-like phenotypes in transgenic mice.
    Schilling G; Savonenko AV; Klevytska A; Morton JL; Tucker SM; Poirier M; Gale A; Chan N; Gonzales V; Slunt HH; Coonfield ML; Jenkins NA; Copeland NG; Ross CA; Borchelt DR
    Hum Mol Genet; 2004 Aug; 13(15):1599-610. PubMed ID: 15190011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin.
    Damiano M; Diguet E; Malgorn C; D'Aurelio M; Galvan L; Petit F; Benhaim L; Guillermier M; Houitte D; Dufour N; Hantraye P; Canals JM; Alberch J; Delzescaux T; Déglon N; Beal MF; Brouillet E
    Hum Mol Genet; 2013 Oct; 22(19):3869-82. PubMed ID: 23720495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental mutagenesis of huntingtin to map cleavage sites: different outcomes in cell and mouse models.
    Tebbenkamp AT; Xu G; Siemienski ZB; Janus C; Fromholt SE; Brown HH; Swing D; Tessarollo L; Borchelt DR
    J Huntingtons Dis; 2014; 3(1):73-86. PubMed ID: 25062766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
    Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
    Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
    Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
    Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
    Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
    J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial behavioral effects of chronic cerebral dopamine neurotrophic factor (CDNF) infusion in the N171-82Q transgenic model of Huntington's disease.
    Stepanova P; Kumar D; Cavonius K; Korpikoski J; Sirjala J; Lindholm D; Voutilainen MH
    Sci Rep; 2023 Feb; 13(1):2953. PubMed ID: 36807563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment.
    Lin MS; Liao PY; Chen HM; Chang CP; Chen SK; Chern Y
    J Neurosci; 2019 Feb; 39(8):1505-1524. PubMed ID: 30587542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntington's disease.
    Hyeon SJ; Park J; Yoo J; Kim SH; Hwang YJ; Kim SC; Liu T; Shim HS; Kim Y; Cho Y; Woo J; Kim KS; Myers RH; Ryu HL; Kowall NW; Song EJ; Hwang EM; Seo H; Lee J; Ryu H
    Prog Neurobiol; 2021 Sep; 204():102110. PubMed ID: 34166773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Effect of Berberine on Huntington's Disease Transgenic Mouse Model.
    Jiang W; Wei W; Gaertig MA; Li S; Li XJ
    PLoS One; 2015; 10(7):e0134142. PubMed ID: 26225560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.